IPO registrations (S-1, F-1) · Registrants
Zomedica Corp.
- SEC CIK
- 1684144 · filings on EDGAR ↗
- Name on the registration
- Zomedica Pharmaceuticals Corp.
- Former names
- Zomedica Pharmaceuticals Corp. (2016–2020)
- Registration
- Form S-1, first filed 2017-04-21, last 2020-06-18; 3 initial registrations, 7 amendments
- Outcome
- Final prospectus filed 2017-11-21; declared effective 2017-11-20
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- A0
- Business address
- 1101 TECHNOLOGY DRIVE, SUITE 100, Ann Arbor, MI 48108
- Ticker
- ZOMDF (OTC)
- EDGAR entity type
- operating
- Insiders and CEO pay
- Zomedica Corp. on the corporate pages
On this site
- Business registration: ZOMEDICA INC. Fuzzy (name and state)
- Business registration: ZOMEDICA INC. Fuzzy (name and state)
- Business registration: ZOMEDICA INC. Fuzzy (name and state)
- Business registration: ZOMEDICA INC. Fuzzy (name and state)
- Business registration: ZOMEDICA INC. Fuzzy (name and state)
- Federal award recipient: ZOMEDICA INC. Fuzzy (name and state)
- Form D issuer: Zomedica Pharmaceuticals Corp. EXACT (CIK (EXACT))
- SEC filer: Zomedica Corp. EXACT (CIK (EXACT))
- Person page: Jeffrey M Rowe Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
Filings 22
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2017-04-21 | S-1 | S-1 (registration) | Zomedica Pharmaceuticals Corp. | 0001171843-17-002245 ↗ |
| 2017-05-24 | S-1/A | S-1/A (amendment) | Zomedica Pharmaceuticals Corp. | 0001171843-17-003294 ↗ |
| 2017-09-01 | S-1/A | S-1/A (amendment) | Zomedica Pharmaceuticals Corp. | 0001171843-17-005341 ↗ |
| 2017-11-09 | S-1/A | S-1/A (amendment) | Zomedica Pharmaceuticals Corp. | 0001171843-17-006837 ↗ |
| 2017-11-15 | S-1/A | S-1/A (amendment) | Zomedica Pharmaceuticals Corp. | 0001171843-17-007051 ↗ |
| 2017-11-20 | S-1/A | S-1/A (amendment) | Zomedica Pharmaceuticals Corp. | 0001171843-17-007179 ↗ |
| 2017-11-20 | EFFECT | EFFECT (declared effective) | Zomedica Pharmaceuticals Corp. | 9999999995-17-003024 ↗ |
| 2017-11-21 | 424B4 | 424B4 (final prospectus) | Zomedica Pharmaceuticals Corp. | 0001171843-17-007183 ↗ |
| 2018-03-30 | EFFECT | EFFECT (declared effective) | Zomedica Pharmaceuticals Corp. | 9999999995-18-000721 ↗ |
| 2018-04-04 | 424B4 | 424B4 (final prospectus) | Zomedica Pharmaceuticals Corp. | 0001171843-18-002522 ↗ |
| 2019-01-30 | EFFECT | EFFECT (declared effective) | Zomedica Pharmaceuticals Corp. | 9999999995-19-000038 ↗ |
| 2019-02-08 | 424B4 | 424B4 (final prospectus) | Zomedica Pharmaceuticals Corp. | 0001171843-19-000823 ↗ |
| 2019-03-18 | EFFECT | EFFECT (declared effective) | Zomedica Pharmaceuticals Corp. | 9999999995-19-000451 ↗ |
| 2020-05-15 | S-1 | S-1 (registration) | Zomedica Pharmaceuticals Corp. | 0001171843-20-003777 ↗ |
| 2020-05-21 | S-1/A | S-1/A (amendment) | Zomedica Pharmaceuticals Corp. | 0001171843-20-003903 ↗ |
| 2020-05-22 | S-1/A | S-1/A (amendment) | Zomedica Pharmaceuticals Corp. | 0001171843-20-003958 ↗ |
| 2020-05-26 | EFFECT | EFFECT (declared effective) | Zomedica Pharmaceuticals Corp. | 9999999995-20-001253 ↗ |
| 2020-05-27 | 424B4 | 424B4 (final prospectus) | Zomedica Pharmaceuticals Corp. | 0001171843-20-004016 ↗ |
| 2020-06-18 | S-1 | S-1 (registration) | Zomedica Pharmaceuticals Corp. | 0001171843-20-004434 ↗ |
| 2020-06-26 | 424B4 | 424B4 (final prospectus) | Zomedica Pharmaceuticals Corp. | 0001171843-20-004585 ↗ |
| 2020-06-26 | EFFECT | EFFECT (declared effective) | Zomedica Pharmaceuticals Corp. | 9999999995-20-001697 ↗ |
| 2020-10-26 | EFFECT | EFFECT (declared effective) | Zomedica Corp. | 9999999995-20-002974 ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| DiMarzo Robert | Officer | EVP of Global Strategy | 1 | 2017 | |
| Eagleson Jane | Director | 1 | 2017 | ||
| Herbst Bruk | Officer | Chief Commercial Officer | 6 | 2017–2021 | |
| LeBar James | Director | 5 | 2017–2020 | ||
| Morley Stephanie | Officer | COO & VP of Product Dev; President and COO; President & CMO; President & COO | 10 | 2017–2021 | |
| Robitaille Thomas | Director | 1 | 2017 | ||
| Rowe Family GST Trust | TenPercentOwner | 1 | 2017 | ||
| Rowe Jeffrey M | Director; Director,TenPercentOwner | 11 | 2017–2025 | person page Fuzzy | |
| Shameze Rampertab | Director,Officer; Other | Chief Financial Officer; Interim CEO and CFO | 6 | 2017–2020 | |
| Solensky Gerald JR | Director,Officer,TenPercentOwner | President and CEO | 8 | 2017–2019 | |
| Williams Rodney James | Director | 14 | 2017–2025 | ||
| POWERS JOHNNY D | Director | 29 | 2019–2026 | ||
| Cohen Robert | Director; Director,Officer; Officer | CEO; Interim CEO | 9 | 2020–2025 | |
| MACLEOD CHRISTOPHER ROSS | Director | 8 | 2020–2025 | ||
| Cotter Ann | Officer | CFO and Secretary; Chief Financial Officer & Sec.; Interim CFO | 6 | 2020–2021 | |
| Wolfenberg Christopher | Director | 2 | 2020–2021 | ||
| Whelan Sean | Director | 5 | 2021–2025 | ||
| HEATON LARRY C II | Director,Officer; Officer | CEO; President | 11 | 2021–2026 | |
| Lock Adrian | Officer | VP and General Manager | 3 | 2021–2022 | |
| Blair Anthony K | Officer | Chief Operating Officer; COO | 9 | 2022–2026 | |
| DeHaan-Fullerton Karen | Officer | Chief Counsel and Secretary; General Counsel; General Counsel/Corporate Secy | 5 | 2022–2026 | |
| Nichols Pamela | Director | 5 | 2022–2025 | ||
| Donato Peter | Officer | Chief Financial Officer | 4 | 2023–2024 | |
| Klass Russell Kevin | Officer; Other | Sr Vice President of Sales; Sr Vice President, Sales; Sr. Vice President, Sales; Vice President of Sales | 19 | 2023–2026 | |
| Jordan Scott | Officer | Chief Financial Officer | 3 | 2025 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2020-02-14 | Zomedica Pharmaceuticals Corp. | Other Health Care | Indefinite | $0 | 2 | 1 |
| 2019-05-30 | Zomedica Pharmaceuticals Corp. | Pharmaceuticals | $20,000,000 | $12,000,000 | 1 | 1 |
| 2018-05-18 | Zomedica Pharmaceuticals Corp. | Pharmaceuticals | $10,000,000 | $550,000 | 3 | 1 |
| 2018-05-18 | Zomedica Pharmaceuticals Corp. | Pharmaceuticals | $1,250,000 | $1,250,000 | 1 | 1 |
| 2017-08-02 | Zomedica Pharmaceuticals Corp. | Pharmaceuticals | $10,082,751 | $3,319,997 | 3 | 1 |
| 2017-01-04 | Zomedica Pharmaceuticals Corp. | Pharmaceuticals | $7,389,740 | $866,000 | 3 | 1 |
| 2017-01-04 | Zomedica Pharmaceuticals Corp. | Pharmaceuticals | $3,704,263 | $3,704,263 | 20 | 1 |
| 2016-09-08 | Zomedica Pharmaceuticals Corp. | Pharmaceuticals | $3,875,489 | $3,875,489 | 20 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.